Aim To test whether an incentive-based intervention that increased adherence to naltrexone also increased opiate abstinence. Design Post-hoc combined analysis of three earlier randomized controlled trials that showed individually that incentives for adherence to oral and to extended-release injection naltrexone dosing schedules increased naltrexone adherence, but not opiate abstinence. Setting Out-patient therapeutic work-place in Baltimore, MD, USA. Participants One hundred and forty unemployed heroin-dependent adults participating from 2006 to 2010. Interventions Participants were hired in a model work-place for 26 weeks and randomized to a contingency (n = 72) or prescription (n = 68) group. Both groups were offered naltrexone. Contingency participants were required to take scheduled doses of naltrexone in order to work and earn wages. Prescription participants could earn wages independent of naltrexone adherence.
INTRODUCTION
Naltrexone could be an ideal medication for the treatment of opioid use disorder because it blocks the subjective, reinforcing and physiological effects of opioids [1] ; has no abuse liability; and is less regulated [2] . However, a major limitation is that fewer than one-third of participants who begin taking naltrexone adhere to the medication in the long term (e.g. 6 months) [3] . An extended-release injectable suspension of naltrexone (XR-NTX) was developed and is approved for the treatment of opioid use disorder in the United States. XR-NTX appears to improve adherence compared to oral naltrexone [4] , but adherence rates are still poor [5] [6] [7] [8] [9] .
In addition to poor adherence, clinical trials evaluating oral naltrexone and XR-NTX have suffered from low and differential retention and differential rates of urine sample collection between treatment groups [3, 5, 10] , which has prevented appropriate evaluations of the effects of naltrexone on opioid use [11] . An exception to these limitations is a recent open-label trial among criminal justice offenders in the United States [12] , which found that XR-NTX increased time to relapse and opioid abstinence compared to treatment as usual. Although these findings are encouraging, only 61% of participants accepted all six injections.
To address poor adherence, we have been systematically evaluating a contingency management intervention [13] that uses employment-based incentives to promote long-term adherence to naltrexone treatment. Under this intervention, incentives are delivered as wages to participants whom we hire and pay to work in a model workplace where they complete job skills training. To promote naltrexone adherence, some participants are assigned randomly to a contingency group in which they are required to take scheduled doses of naltrexone in order to work and earn maximum pay. Others are assigned to a prescription group that is offered naltrexone but can work and earn wages independent of taking naltrexone. Because all participants can work and earn wages, this research model produces high rates of retention and data collection in both groups. This has permitted a rigorous analysis of the effects of naltrexone adherence on opiate abstinence.
In three controlled clinical trials using this model [14] [15] [16] , we showed that unemployed, heroin-dependent adults who were assigned randomly to the contingency group took significantly more doses of oral and XR-NTX [14, 16] naltrexone than those assigned to the prescription group. These trials demonstrated that an incentive-based intervention can increase naltrexone adherence. However, none of the trials showed significant between-group differences on opiate abstinence despite consistently higher rates of opiate abstinence among those assigned to the contingency versus prescription group.
The purpose of the present study was to combine data from our three earlier trials, thereby achieving a larger overall sample size. We chose these trials because they are the only ones, to our knowledge, that evaluate the use of incentives for naltrexone adherence and are not confounded by differential rates of data collection. The primary aim was (1) to test whether an incentive-based intervention targeting adherence to oral naltrexone and extended-release injectable suspsensions increased opiate abstinence. Because cocaine use and naltrexone nonadherence were both associated with opiate use in the original trials, secondary aims were (2) to test whether cocaine use during the intervention altered the effect of naltrexone adherence on opiate abstinence and (3) to determine if naltrexone adherence was responsible for the intervention effects on opiate abstinence by testing the effects of the intervention while controlling for naltrexone adherence.
METHODS

Design
This was an individual patient post-hoc analysis in which we combined and analyzed data from three previously published clinical trials conducted from 2006 to 2010 [14] [15] [16] . Each trial evaluated the same employment-based incentive intervention for naltrexone adherence implemented in the same setting. One trial used oral naltrexone [15] and two trials used XR-NTX of different formulations (Depotrex ® [16] and Vivitrol ® [14] ). Full details on each trial have been reported elsewhere [14] [15] [16] . The methods and outcome measures for each trial were identical unless noted otherwise.
Participants
Participants (n = 140) of the original trials were recruited from opioid detoxification programs and street outreach; were not interested in methadone or buprenorphine maintenance treatment; were aged at least 18 years; lived in or near Baltimore City in Maryland, USA; were unemployed; met DSM-IV criteria for opioid dependence; [17] selfreported using heroin on at least 21 of the last 30 days while living in the community; and were medically approved for naltrexone. The oral naltrexone trial [15] also required that participants report injection drug use in the last 30 days, have visible track marks and provide a urine sample that tested positive for both opiates and cocaine upon entry into opioid detoxification. Individuals were excluded if they had current hallucinations, delusions or thought disorders; had current homicidal or suicidal ideation; were currently incarcerated, in a halfway house or under constant monitoring; earned more than $200 in taxable income in the past 30 days; were pregnant or breastfeeding; were required to use opioids for medical purposes; had physical limitations that prevented use of a keyboard; or had serum aminotransferase levels more than three times above normal.
Treatment context
The original trials were conducted in the Therapeutic Workplace, a model work-place where participants could earn hourly wages for participating in jobs skills training [18] . Participants could work 4 hours each week day and earn $8 per hour in hourly pay plus approximately $2 per hour for their performance on training programs. All participants were offered individual substance abuse counseling.
Assessments
The main assessments collected at intake included the Addiction Severity Index-Lite [19] to evaluate medical, substance use, legal, educational, employment and family histories; and the Composite International Diagnostic Interview [20] , a diagnostic tool for psychiatric disorders. Liver function tests were performed routinely, and participants who became pregnant or had significantly abnormal liver function were discontinued from naltrexone. Urine samples were collected under direct observation and tested for opiates and cocaine every Monday, Wednesday and Friday. Additional assessments were conducted each month in conjunction with collection and testing of urine samples for opiates, cocaine, buprenorphine, methadone, benzodiazepines and amphetamines. Use of drugs other than opiates and cocaine was rare (< 7% of samples tested).
Naltrexone induction
All participants completed extended or brief in-patient detoxification before being invited to attend the Therapeutic Workplace. Participants who completed extended in-patient detoxification were inducted immediately onto oral naltrexone. Those completing brief in-patient detoxification were required to continue out-patient detoxification at the Therapeutic Workplace, and during this time attendance and wages were contingent upon providing opioidnegative samples. Induction onto oral naltrexone was guided by clinical judgment, and all participants reached maintenance doses of 100 mg on Monday and Wednesday and 150 mg on Friday. The induction phase lasted approximately 2 weeks for the XR-NTX trials [14, 16] or 4 weeks for the oral naltrexone trial [15] .
Experimental groups
Following oral naltrexone induction, participants were invited to the Therapeutic Workplace for 26 weeks, and assigned randomly to a contingency or prescription group with stratification by attendance, opiate-negative urine samples and cocaine-negative urine samples during the study induction period. Contingency participants were required to take scheduled doses of naltrexone to attend the Therapeutic Workplace and earn maximum pay. If participants in the contingency group did not take a scheduled dose of naltrexone, they were not permitted to enter the work-place until they resumed naltrexone, and their hourly pay was reset from $8 per hour to $1 per hour. Pay increased by $1 per hour, to the maximum of $8 per hour, for each day of attendance once naltrexone was resumed. Prescription participants could attend the workplace and earn maximum wages independent of naltrexone adherence. Naltrexone formulation and dosing varied across the three trials. For the oral naltrexone trial [15] , adherence was directly observed every Monday (100 mg), Wednesday (100 mg) and Friday (150 mg). The XR-NTX Depotrex ® trial [16] verified receipt of injections given once every 3 weeks, and the XR-NTX Vivitrol ® trial [14] verified receipt of injections given once every 4 weeks. Participants assigned to the prescription groups in the oral naltrexone trial were given a monthly supply of oral naltrexone [15] or offered injections at the appropriate intervals for the XR-NTX trials [14, 16] . All medications were provided at no cost to participants.
Outcome measures
The primary outcome measures were adherence to naltrexone, opiate abstinence and cocaine abstinence. Adherence in the oral naltrexone trial [15] was defined as providing a urine sample at monthly assessments that tested positive for naltrexone (i.e. ≥ 5 ng/ml). Adherence in the XR-NTX trials [14, 16] was observed directly. At monthly assessments, participants were categorized as under naltrexone blockade based on their urine sample for the oral naltrexone trial [15] or whether they were within the protection window for the XR-NTX trials (3 weeks for Depotrex ® [16] and 4 weeks for Vivitrol ® [14] ). Opiate and cocaine abstinence were assessed from urine samples collected thrice weekly and at monthly assessments. If urinary morphine or benzoylecgonine concentrations were at or below 300 ng/ml, the sample was considered negative for opiates or cocaine, respectively.
Data analysis
Participant characteristics at intake were compared across treatment groups using χ 2 tests for categorical variables and t-tests for continuous variables. The main analyses were based on data from when the naltrexone incentive intervention was in effect, which varied across trials. For urine samples collected thrice weekly, the number of samples included was 54 for the XR-NTX Depotrex ® trial [16] , 72 for the XR-NTX Vivitrol ® trial [14] and 78 for the oral naltrexone trial [15] . For urine samples collected at monthly assessments, the number of samples included was four for the XR-NTX Depotrex ® trial [16] , five for the XR-NTX Vivitrol ® trial [14] and six for the oral naltrexone trial [15] . Missing urine samples were analyzed both as missing-positive (missing samples counted as positive) and missing-missing (missing samples omitted from calculations) for opiates and cocaine and are reported as missing-positive unless noted otherwise. Tests of urine samples for adherence from the oral naltrexone trial [15] were analyzed as missing-negative (missing samples counted as negative). Longitudinal mixed effects regression models [21] with random effects for both study and participant were used to account for heterogeneity across trials. These models give equal weight to early and later outcomes during the intervention. These analyses were used to evaluate the effects of the incentive-based intervention (contingency versus prescription groups) on naltrexone adherence, drug abstinence and their relationships. All analyses were intent-to-treat and were adjusted for attendance, opiate-negative urine samples and cocaine-negative urine samples during the induction period. Statistical analyses were conducted using Stata version 13 [22] , and alpha was set at 0.05. Table 1 displays participant characteristics at intake by group collapsed across trials. Participants were mostly male, black, middle-aged and dependent on cocaine. More than one-third had not completed high school or earned a General Educational Development test (GED), and approximately half were on parole or probation. The only significant difference between groups was on past 30-day income obtained from employment, but for both groups this income was very small.
RESULTS
Participant characteristics
Effect of incentives for naltrexone adherence
Contingency participants had significantly higher rates of naltrexone adherence than prescription participants (Table 2) . Significantly more participants in the contingency group also had perfect adherence to naltrexone throughout the study than participants in the prescription group (Table 2) .
Associations of naltrexone adherence, cocaine abstinence and opiate abstinence Naltrexone adherence was associated with significantly more opiate-negative urine samples at monthly assessments (Fig. 1b) . Rates of opiate-negative samples were 85.0% when participants were under naltrexone blockade compared to 62.7% when participants were not under blockade [missing-missing, odds ratio (OR) = 3.6, 95% confidence interval (CI) = 2.5-5.4, P < 0.01]. Urine samples that tested negative for cocaine were significantly more likely to also test negative for opiates, both at monthly (missing-missing, OR = 17.5, 95% CI = 10.6-29.1, P < 0.01) and thrice-weekly assessments (missing-missing, OR = 11.5, 95% CI = 9.8-13.5, P < 0.01). Rates of opiate-negative urine samples were 92.5% when samples were cocaine-negative compared to 49.6% when samples were cocaine-positive at monthly assessments (Fig. 1) . For urine samples collected thrice weekly, rates of opiate-negative urine samples were 93.8% when urine samples were cocaine-negative compared to 58.3% when cocaine-positive.
The adverse relation of cocaine use to opiate abstinence occurred for both contingency and prescription participants (Fig. 1a) and when participants were and were not under naltrexone blockade (Fig. 1b) . The association of naltrexone blockade with opiate abstinence was still significant after controlling for cocaine-positive samples (Fig. 1b) . There were no significant interactions between cocaine use and group or between cocaine use and naltrexone blockade.
Effect of incentives for naltrexone adherence on opiate and cocaine abstinence
During the 1-week period prior to randomization, contingency and prescription participants did not differ significantly on rates of opiate-negative urine samples (92.6 versus 92.7%, respectively, P = 0.99) or cocaine- Odds ratios (OR) are from a mixed-effects longitudinal regression model with random effects for both trial and subject. Outcome variable was not expected to change based on covariate, and so analysis was not performed. The relationship between naltrexone adherence and opiate use was not possible to determine for thrice-weekly urinalyses; thrice-weekly adherence data were not collected from both groups in all trials. Figure 1 Percentage of urine samples negative for opiates during the intervention period by whether the sample was cocaine-positive, arranged by (a) whether the sample was submitted by a contingency or prescription group participant and (b) whether the sample was submitted while under naltrexone blockade. Numbers above each bar indicate the number of opiate-negative samples and total number within the category. Each odds ratio is shown with its 95% confidence interval. *Comparison statistically significant (P < 0.05); †comparison controlled for cocaine urinalysis. Data are from monthly urine assessments for all three trials. Missing data were considered missing negative urine samples (81.0 versus 77.5%, respectively, P = 0.58). Table 2 shows observed rates and regression results for opiate abstinence, cocaine abstinence and collection rates during the intervention period. Collection rates did not differ significantly between the contingency and prescription groups. Contingency participants submitted higher rates of opiate-negative urine samples than prescription participants (Table 2, Fig. 2 ). This effect was significant for thrice-weekly urinalyses for both methods of handling missing data (missing-positive and missing-missing) but not for monthly urinalyses (P = 0.06). There were no significant differences on any measures of cocaine abstinence between the contingency and prescription participants.
When we controlled for cocaine-positive samples, contingency participants had significantly higher rates of opiate-negative urine samples than prescription participants for monthly and thrice-weekly samples (Table 2) . A separate regression analysis that adjusted for naltrexone adherence revealed that the effect of incentives on monthly opiate abstinence decreased for missing-missing and missing-positive samples ( Table 2 ), suggesting that greater opiate abstinence in the contingency participants was due to increased adherence to naltrexone.
DISCUSSION
The present analysis showed that incentives for naltrexone adherence produced statistically significant increases in opiate abstinence. Compared to participants who could earn incentives independent of taking naltrexone, those required to take scheduled doses of naltrexone to earn incentives had a 43% increase in adherence to naltrexone and an approximately 10-17% increase in rates of opiatenegative urine samples, depending on the measure used (see Table 2 ). The magnitude of the opiate abstinence effect was small relative to the magnitude of the naltrexone adherence effect. Cocaine use was high in the study populations, and cocaine use was associated with decreases in opiate abstinence. When we controlled for cocaine use, participants exposed to incentives for naltrexone adherence (i.e. contingency participants) had significantly higher rates of opiate abstinence than participants not exposed to those incentives (i.e. prescription participants). Importantly, when the analysis that assessed the effect of incentives on opiate abstinence was adjusted for naltrexone adherence, the effect of incentives for naltrexone adherence on opiate abstinence was reduced. This suggests that higher rates of opiate abstinence for participants who received incentives for naltrexone adherence (contingency group) were due to increased naltrexone adherence.
In the absence of psychosocial interventions that target medication adherence, naltrexone's effectiveness is limited, even with the newer Food and Drug Administration (FDA)-approved XR-NTX formulation designed specifically to limit dosing frequency and improve adherence. In the three trials reported here, nearly two-thirds of scheduled doses were not taken when incentives for adherence were not provided. Offering incentives for taking scheduled doses of naltrexone more than doubled rates of adherence and promoted increases in opiate abstinence.
Although incentives increased naltrexone adherence and, in turn, opiate abstinence, some participants continued to use opiates while under naltrexone blockade [23, 24] . In the present analysis, we found that challenging the naltrexone blockade was associated strongly with cocaine use. Of the 58 monthly samples that tested positive for opiates while under blockade, 49 (84.5%) also tested positive for cocaine. Why cocaine use is associated with opiate use for participants under naltrexone blockade is unclear. Participants may have used both drugs concurrently and through the same route (i.e. 'speedballing') or opiate use may have simply been more likely when participants were in cocaine-using environments. For Cocaine use throughout the trials was associated negatively with opiate abstinence. The use of incentives to promote cocaine abstinence is effective among individuals receiving agonist treatment for opioid use disorder [25] and may be necessary to maximize the effectiveness of antagonist treatment among individuals who take naltrexone but continue to use cocaine. The use of incentives to promote opiate abstinence is also effective among individuals receiving agonist treatment for opioid use disorder [26, 27] and could also be used to enhance further the effectiveness of antagonist treatment among individuals who take naltrexone but continue to use opiates under naltrexone blockade.
Although we used the same outcomes and data analytical approach that was reported in each of the three earlier individual trials, a notable limitation of the present study was that it was conducted as a post-hoc analysis. This was conducted because of the importance of determining whether beneficial effects on naltrexone adherence translated to beneficial effects on opiate use, and because the individual trials were underpowered to detect a significant difference on opiate abstinence.
Due to concerns regarding poor adherence, naltrexone use as a primary treatment for opioid use disorder has been discouraged except for individuals who are highly motivated to stop using opioids, such as health-care professionals [28] and criminal justice offenders [12] who may face job loss and/or incarceration for continuing opioid use. However, the analysis reported here shows that, by harnessing the power of incentives, challenging populations who are not interested in agonist therapy can be motivated to adhere to naltrexone and that this treatment can increase opiate abstinence. Future work should evaluate models of extending and maintaining incentive-based interventions to promote long-term naltrexone adherence and drug abstinence [29] .
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